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Challenges in drug development of neurological diseases remain mainly ascribed to the
blood–brain barrier (BBB). Despite the valuable contribution of animal models to drug dis-
covery, it remains difficult to conduct mechanistic studies on the barrier function and
interactions with drugs at molecular and cellular levels. Here we present a microphysiological
platform that recapitulates the key structure and function of the human BBB and enables 3D
mapping of nanoparticle distributions in the vascular and perivascular regions. We demon-
strate on-chip mimicry of the BBB structure and function by cellular interactions, key gene
expressions, low permeability, and 3D astrocytic network with reduced reactive gliosis and
polarized aquaporin-4 (AQP4) distribution. Moreover, our model precisely captures 3D
nanoparticle distributions at cellular levels and demonstrates the distinct cellular uptakes and
BBB penetrations through receptor-mediated transcytosis. Our BBB platform may present a
complementary in vitro model to animal models for prescreening drug candidates for the
treatment of neurological diseases.
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The blood–brain barrier (BBB) is a highly functionalizedvascular border of the central nervous system (CNS) thatregulates the transport of substances between the blood
and brain1. The barrier function is attributed mainly to the
unique perivascular structure specialized by a three-dimensional
(3D) network of astrocytes that communicate with endothelial
cells and pericytes (Fig. 1a)2. Astrocytes form the glia limitans of
the BBB with their end-feet contacting the blood vessels and
control the influx of water through aquaporin-4 (AQP4)3,4.
Pericytes embedded in the basement membrane wrap around the
endothelium and contribute to astrocytic polarization5. These
complex cellular interactions at the BBB maintain its integrity
and restrict the penetration of drugs, leading to a low success rate
in the development of therapeutics for CNS diseases6.
To deliver drugs across this barrier, CNS delivery systems have
been widely explored to cross the BBB7, including nanoparticle
(NP)-mediated drug delivery with ligands specific to BBB endo-
thelial surface receptors8,9. In particular, high-density lipoprotein
(HDL)-mimetic NPs have been introduced as promising CNS
delivery systems due to the innate endogenous character to
facilitate the delivery of therapeutic molecules across the BBB via
lipoprotein receptor-mediated transcytosis10–12. However, the
lack of experimental models that can precisely evaluate the
interactions between the BBB and delivery carriers restricts suc-
cessful clinical translation of therapeutic and diagnostic NPs13,14.
Animal models often do not predict drug responses in humans
due to species differences15–17. Moreover, the complex physiology
of animal models makes it difficult to perform mechanistic stu-
dies and direct quantitative analysis of NPs with the barrier at
molecular and cellular levels in real time13. These challenges
highlight the importance of developing an in vitro model that
mimics the essential physiological structure and function of the
human BBB and that reproduces the key relationships of healthy
and disrupted barrier functions in a controlled manner.
Recent advances in organ-on-a-chip technology have provided
the ability to recapitulate the microenvironment of the BBB18,19.
Existing in vitro human BBB-on-chip models have made efforts
to reconstitute the tight endothelial barrier function using several
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Fig. 1 Microengineered human blood–brain barrier (BBB) model. a Schematic description of the BBB consisting of endothelial cells (ECs) along the blood
vessel under continuous blood flow, pericytes covering the endothelial monolayer, and astrocytes with aquaporin-4 (AQP4) expression at their end-feet
near the blood vessel. b Schematic description of our microengineered human BBB model. c 3D configuration of the BBB model showing human brain
microvascular endothelial cells (HBMECs) (ZO-1, red) and human astrocytes (HAs) (GFAP, white) (scale bar= 100 µm). d Explosion view of the device
consisting of upper vascular layer, porous membrane, lower perivascular layer, and glass slide. e A photo of the device after completing fabrication of the
device (blue: upper channel and red: lower channels) (scale bar= 500 µm). f Lower layer consisting of three parallel channels separated by series of
micropillars (red: center channel) (scale bar= 500 µm). g Cross-section of the device after fabrication (along A-B in Fig. 1f) (scale bar= 200 µm). h Cell
metabolic activities assessed by a (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay (E+G:
1:1:1 mixture of endothelial medium, astrocyte medium, and microglia medium, E+G+ P: 1:1:1:1 mixture of endothelial medium, astrocyte medium,
microglia medium, and pericyte medium) (Data represent mean ± s.d. of n= 6 for each condition, *p < 0.05 and ****p < 0.001 versus each cell culture
medium by student t-test). i Bottom view of the device with endothelial monolayer (ZO-1, red) and astrocytic network (GFAP, white) (scale bar= 50 µm).
j Endothelial monolayer (ZO-1, red) supported by a layer of human brain vascular pericytes (HBVPs) (α-SMA, green) (scale bar= 50 µm). k Aquaporin-4
(AQP4, yellow) and α-syntrophin (α-syn, magenta) expressions at astrocytic end-feet (GFAP, white) underneath a porous membrane (indicated as the
dotted line) in the lower channel (Blue arrows indicate co-localization of AQP4 with α-syn.) (scale bar= 50 µm). All images are representative ones from
at least five biological and three technical replicates.
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platforms that include monoculture of brain endothelial cells20
and co-culture of endothelial cells with astrocytes in two-
dimensional (2D)21 and 3D22,23 microenvironments. A recent
BBB model with 3D culture of endothelial cells, pericytes, and
astrocytes enabled reconstitution of direct cellular interactions,
resulting in the barrier function with permeability lower than
previous in vitro models of mono-culture or co-culture24. How-
ever, it remains difficult to incorporate the complex physiology of
astrocytes into the in vitro BBB models and demonstrate the
contribution of astrocytes to the BBB’s health and disruption. In a
healthy brain, astrocytes show branched processes around their
cell bodies25 and concentrated expression of AQP4 at their end-
feet processes near vasculature4,26,27. In response to CNS injuries
or diseases, astrocytes become reactive, which contribute to BBB
breakdown and disease progression such as neurodegeneration,
ischemia, and infection28. Reactive astrocytes undergo changes
in morphology and gene expressions including lipocalin-2
(LCN2) and Serpin Family A Member 3 (Serpina3)29. In vitro
BBB models thus would be enhanced and widely useful for CNS
disease modeling if healthy and reactive astrocytes could be
reconstituted in a controlled manner.
Here we present a microengineered physiological system
designed to model the human BBB with brain endothelial cells,
pericytes, and 3D astrocytic network (Fig. 1b). The use of human
brain microvascular endothelial cells (HBMECs) in our BBB chip
enables the reproduction of BBB-specific endothelial character-
istics with greater gene expressions of junctional markers,
membrane transporters and receptors, resulting in a tight barrier
with permeability comparable to recent tri-culture models.
Importantly, our BBB chip creates a 3D astrocytic network with
polarized expression of AQP4 and decreased reactive gliosis
markers including LCN2. The reduced reactive astrogliosis allows
for neuroinflammation modeling in response to extrinsic stimuli
of pro-inflammatory factors such as interleukin-1β (IL-1β). The
model combined with high-precision sampling and flow cyto-
metric analysis enables on-chip quantification of nanoparticle
transport and distribution in the vascular and perivascular
regions at cellular and tissue levels. Our BBB chip may provide a
reliable tool for better understanding of drug distribution and
efficacy at the BBB in both physiological and pathological
conditions.
Results
Microengineered human BBB model with 3D astrocytic net-
work. Our microengineered human BBB model reconstitutes the
BBB structure with the brain vascular endothelium and human
brain vascular pericytes (HBVPs) in direct contact with 3D net-
work of human astrocytes (HAs) (Fig. 1b, c). The BBB chip has
two compartmentalized microfluidic channel layers that combine
a 2D endothelial monolayer with a 3D brain microenvironment,
enabling highly sensitive quantification of molecular distribution
in each space independently (Fig. 1d, e). The upper layer of the
device mimics the vascular space of the brain microvasculature
where an endothelial monolayer is formed on a 7 µm thick porous
membrane (8 µm diameter pores at a density of 1E5 pores cm−2)
with 16 µLmin−1 of continuous fluid flow (shear stress: 4 dyne
cm−2). The lower layer accommodates pericytes underneath the
membrane and astrocytes in a 3D Matrigel (5 mgmL−1) in the
center channel along with the two side channels (Fig. 1f). This
structure allows for the 3D astrocyte culture in a hydrogel that is
inserted into the center channel and is stably maintained by
surface tension. Importantly, the edges of the upper channel are
aligned to cover the both side arrays of micropillars (Fig. 1g) to
avoid the undesirable leakage that may occur in the edge of a
microfluidic device of rectangular cross-section due to
heterogeneous formation of an endothelial monolayer at the
channel walls, which we recently demonstrated with a micro-
fluidic transcellular monitor30. The device is designed to have
diffusive transport of culture medium components into the
hydrogel channel with media refreshment in the upper and the
two side channels (Supplementary Fig. 1). Moreover, the two side
channels promote independent lateral perfusion through the
hydrogel enabling efficient removal of metabolic wastes or
unbound antibodies and, more importantly, provide the oppor-
tunity to precisely sample solutions perfused from the hydrogel
without disturbing the cellular organization.
With morphological and metabolic activity assays (see
Methods for details) in the co-culture medium selection (Fig. 1h
and Supplementary Fig. 2), we developed a culture protocol
(Supplementary Figs. 3 and 4), with which we were able to
establish the human BBB integrity after 2.5 days of culture, as the
culture time was also suggested and validated in previous
studies21,31. Our BBB model reproducibly maintains the 3D
network of HAs with physiologically relevant morphology
underneath the endothelial monolayer and across the lower
channel layer (Fig. 1i). The monolayers of HBMECs and HBVPs
on the opposite sides of the 7 µm-thick porous membrane
(Fig. 1j) while the proximity and perfusable structure allow for the
paracrine and juxtacrine signaling between the three cells. More
importantly, our BBB chip clearly demonstrated that HAs in a 3D
network extend their end-feet with higher AQP4 and α-
syntrophin (α-syn) expressions right underneath the porous
membrane over the basal side of the endothelium (Fig. 1k).
Brain-specific endothelial barrier fuction. The brain vascular
endothelium is a highly specialized gatekeeper with complex
transport mechanisms6,32. The critical barrier function of the BBB
endothelium is reportedly characterized by high expressions of
BBB-specific proteins33,34, including junctional, transporter, and
receptor proteins and by high transendothelial electrical resis-
tance (TEER) (i.e., low permeability)35. In addition, applications
of specific human cell sources have enhanced the physiological
relevance of in vitro models to the unique properties of the BBB
endothelium24. In our present study thus, we first demonstrated
that our brain-specific endothelial cells, when cultured with the
other BBB cells (i.e., astrocytes and pericytes), exhibited increases
in representative gene expressions including proteins that regulate
junctional formation, carrier-mediated transport, active efflux,
and amyloid beta (Aβ) transport (Fig. 2a). Especially, BBB cellular
interactions upregulated the endothelial gene expressions of the
representative junctional proteins such as occludin (OCLN),
zonula occludens-1 (ZO-1), and vascular endothelial cadherin
(VE-cad) (Fig. 2b) and the representative membrane transporters
and receptors including glucose transporter 1 (GLUT1), choles-
terol efflux regulatory protein (CERP; ATP-binding cassette sub-
family A member 1, ABCA1), and low-density lipoproetin
receptor-related protein 1 (LRP1) (Fig. 2c).
In our BBB chip, HBMECs cultured in the vascular channel
under a physiological shear stress (4 dyne cm−2)36 establish an
intact monolayer with tight junctions (Fig. 2d) while HBVPs are
cultured on the other side of the porous membrane in the
perivascular channel (Fig. 2e). More importantly, HAs in a
hydrogel of the perivascular channel exhibit a typical star-shaped
morphology with radial distribution of fine branches and their 3D
cellular network (Fig. 2f, g). This 3D cellular structure in our BBB
chip allows for the highly complex yet organized BBB construc-
tion (Fig. 2h–j), reproducibly leading to the greater barrier
function (Fig. 2k). A physiological level of shear stress was
responsible for inducing endothelial function with the barrier
tightness (Fig. 2l), efflux transporter protein expression
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Fig. 2 Barrier integrity of the endothelial monolayer for the BBB chip. a Heat map of RT-qPCR results of HBMECs in mono-culture and tri-culture systems
(n= 3 for each condition). b, c Gene expression of HBMECs in mono-culture and tri-culture systems including junctional proteins (b) and receptor proteins
(c) (n= 3 for each condition, *p < 0.05 by student t-test). d Tight endothelial monolayer (ZO-1, red; DAPI, blue) formed in the upper channel of the device.
e Pericytes cultured underneath the porous membrane where an endothelial monolayer is constructed on the other side (α-SMA, green; DAPI, blue).
f, g Astrocytes with star-shaped morphology labeled with GFAP (GFAP, white) (f) and S100β (S100β, magenta) (g). h Bi-layer of an endothelial monolayer
(ZO-1, red) and HBVPs (α-SMA, green). i Astrocytic end-feet stretching to the endothelium in 3D cellular network (GFAP, white; DAPI, blue). j 3D BBB
structure constructed in a device (ZO-1, red; α-SMA, green; GFAP, white; DAPI, blue). The fluorescence intensity profiles indicate the distribution of ZO-1,
α-SMA, and GFAP in the image. k Transendothelial electrical resistance (TEER) measured across the membrane between the upper and lower layers with
an endothelial monolayer (EC) and an endothelial monolayer with pericytes and astrocytes (BBB) (n= 11 for EC and n= 12 for BBB, **p < 0.01 by student
t-test). l TEER measured from BBB models under different levels of shear stress (n= 5 for No shear, n= 4 for 0.4 dyne cm−1, and n= 12 for 4 dyne cm−2,
*p < 0.05 by student t-test). m Permeability coefficients calculated from the diffusion of 4 kDa and 40 kDa FITC-dextran through a membrane (No cell),
an endothelial monolayer (EC), an endothelial monolayer co-cultured with pericytes and astrocytes (BBB) (n= 4 for each condition, *p < 0.05 and
****p < 0.001 vs. No cell, #p < 0.05 and ##p < 0.01 vs. EC, all by student t-test). Data are presented as mean ± s.e.m. All scale bars= 50 µm. All images are
representative ones from at least five biological and three technical replicates.
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(Supplementary Fig. 5), and endothelial nitric oxide synthase
(eNOS) phosphorylation (Supplementary Fig. 6a, b). Moreover,
our model showed size-dependent molecular transport across the
BBB (Fig. 2m). The TEER values and permeability coefficients to
4 kDa and 40 kDa FITC-dextran were comparable to previous
BBB studies21,24,31. The permeability coefficient of our BBB
model reached as low as the values measured in vivo37.
Reduced reactive gliosis of 3D-cultured astrocytes. Not only is
the vascular endothelial barrier function important to developing
and validating in vitro BBB models, the physiological relevance
provided by perivascular regions is also essential to precisely
recapitulate the BBB structure and function. One difficult yet
important element in reconstituting the BBB is to preserve the
morphological and physiological characteristics of healthy astro-
cytes38. Astrocytes reportedly restore their in vivo-like physiolo-
gical properties such as morphology and functional reactivity in
3D culture systems25,39. We confirmed that HAs cultured on a
2D Matrigel-coated surface were flat and polygonal in shape
(Fig. 3a and Supplementary Fig. 7a). However, HAs cultured in
3D Matrigel exhibited more in vivo-like ramified morphology
(Fig. 3b and Supplementary Fig. 7b). Moreover, the majority of
HAs cultured in 3D featured small cell bodies with radially dis-
tributed thin and long branches, whereas HAs cultured in 2D
exhibited enlarged cell bodies with less and short processes
(Fig. 3c, d).
Reactive astrocytes are characterized by changes in gene
expression as well as morphology. We performed quantitative
analysis on the gene expression of reactive gliosis markers that are
upregulated in pathological conditions to support that 3D-
cultured HAs in our BBB chip are more physiologically relevant
than conventional 2D culture systems. In particular, LCN2 plays
an important role in neuroinflammation by mediating pro-
inflammatory responses in injury40. We found that reactive
gliosis markers, vimentin (VIM) and LCN2, were downregulated
in HAs cultured in 3D compared to those cultured in 2D, while
the level of glial fibrillary acidic protein (GFAP), the representa-
tive astrocyte marker, did not significantly change (Fig. 3e). In
addition, we confirmed that the LCN2 expression level could be
further regulated in a dose-dependent manner in response to an
inflammatory cytokine treatment with IL-1β in the 3D culture as
in 2D (Fig. 3f, g). These results demonstrate the physiological
relevance of 3D-cultured HAs in our BBB chip and indicate the
potential application for reactive astrogliosis modeling such as in
neuroinflammation.
Polarized expression of aquaporin-4 in the BBB chip. Astro-
cytes in the perivascular space play a role in regulating the water
homeostasis in the brain via the water channel protein AQP4 at
their end-feet processes26,41. Localization of AQP4 in astrocytic
end-feet processes is therefore important to recapitulate the BBB
in homeostatic and physiological conditions. Our BBB model
recapitulates a complex 3D network of HAs with expression of
AQP4 along their branches while 2D culture models show dif-
fusively expressed AQP4 in plasma membrane of astrocytes
(Supplementary Fig. 8). We analyzed AQP4 polarization by cal-
culating the ratio of AQP4 labeled along astrocytic end-feet in a
vascular side versus that in a parenchymal side of the perivascular
channel as previously reported4 (Fig. 3h) and by demonstrating
co-localization with α-syn, the immediate anchor for AQP4 that
controls AQP4 polarization to astrocytic end-feet, in the model
(Fig. 3i). The localization of AQP4 in HAs was polarized to the
astrocytic end-feet in the vascular side of the channel when cul-
tured with HBMECs and HBVPs (Fig. 3j, k). The polarized dis-
tribution of AQP4 was significantly induced in the presense of
HBVPs, as previously observed in vivo5. This finding implies that
our model can mimic the water transport system at the BBB,
which is responsible for the homeostasis of ions and water in
the brain.
Nanoparticle transport analysis on chip. One challenge in CNS
drug delivery research is to accurately quantify the transport of
drug compounds into the brain at cellular and molecular levels.
Our BBB chip allows for the monitoring of the interactions
between cells and NPs but also enables us to quantify the dis-
tribution of NPs in vascular and perivascular spaces as well as in
each cell type. To demonstrate these abilities of our system, we
first synthesized a bioinspired nanoparticle that mimics HDL. We
used our microfluidic technology to engineer HDL-mimetic
nanoparticles with apolipoprotein A1 (eHNP-A1) (Fig. 4a), which
reconstitute the physiologically relevant size and composition to
discoidal HDL (Fig. 4b–d). We confirmed through a biodis-
tribution study following intravenous injection of the fluorescent-
dye labeled eHNP-A1 that eHNP-A1 can enter the BBB with ~3%
of relative accumulation in the brain (Fig. 4e, f and Supplemen-
tary Fig. 9). Confocal imaging analysis of the cryosectioned brain
tissue confirmed that the systemically administered eHNP-A1
were localized around the cell nucleus (Fig. 4g).
We then quantified eHNP-A1 distributions in the vascular and
perivascular spaces at the BBB and studied the transport
mechanisms in a controlled manner. We hypothesized that when
a NP solution is introduced into our BBB chip, NPs either remain
in the vascular channel, interact with HBMECs, or translocate
into the perivascular channel in which NPs can interact with
HBVPs or HAs (Fig. 4h–j). With the results of eHNP-A1’s BBB
penetration as shown in our animal study (Fig. 4e–g), we used our
BBB chip to investigate the mechanism by which eHNP-A1 can
get into the brain. We tested the hypothesis that eHNP-A1
primarily leverages scavenger receptor class B type 1 (SR-B1) on
brain endothelial cells to cross the BBB via transcytosis, one of the
major transport mechanisms of natural HDL42,43. After blocking
SR-B1, the amount of eHNP-A1 remaining in the vascular
channel significantly increased (Fig. 4k), whereas the amount of
eHNP-A1 translocated to the perivascular channel was not
significantly changed (Fig. 4l). This result indicates that blocking
SR-B1 activity reduces eHNP-A1 uptake by HBMECs, whereas it
may induce a compensatory upregulation of other receptors or
determinants of endothelial transcytosis such as SNAREs42,44. We
then mapped the 3D distribution of eHNP-A1 in our BBB chip by
compensating NP loss caused by the adsorption to the PDMS
surface (Supplementary Fig. 10). Our results revealed that block
lipid transporter-1 (BLT-1) treatment reduced the amount of
eHNP-A1 that gets into the tissue (EC uptake and perivascular
channel) by ~3 fold (Fig. 4m, n). Cellular uptake of eHNP-A1 was
further quantified using fluorescence-activated cell sorting
(FACS) analysis. The total portion of eHNP-A1 positive cells
was decreased in the BLT-1 treated BBB models (Fig. 4o, p),
indicating that SR-B1 mediates the cellular uptake of eHNP-A1 in
our BBB chip as shown in previous study42. In particular, the
portion of perivascular cells (i.e., HBVPs and HAs) that have
taken up eHNP-A1 was decreased by 38.5% and 53.8%,
respectively with BLT-1 treatment, whereas the portion of
HBMECs with eHNP-A1 was not changed (Fig. 4q).
Discussion
Our on-chip human BBB model successfully recapitulated the key
structure and function of the BBB featuring the highly specialized
brain endothelial monolayer and physiological network of
astrocytes. The hybrid design combining two vertical layers with
three parallel channels enabled the complex BBB co-culture, not
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only establishing a 2D intact brain endothelium and recon-
structing a 3D brain microenvironment with astrocytic network
but also connecting the BBB cells in perfusable proximity for their
intercellular signaling in co-culture. Moreover, the side channels
along with the 3D brain microenvironment allowed for a precise
quantification of NP distributions across the BBB.
Recent in vitro models have demonstrated the importance of
cell source to mimic organ-specific fuction in vitro, as well as for
human disease modeling45,46. In particular, highly complex BBB
organization requires brain-specific cells to be sourced appro-
priately for in vitro modeling, which secures the key character-
istics including the tight barrier function and low permeability
resulting from high expressions of BBB-specific proteins6,32–34,
compared to human umbilical vein endothelial cells (HUVECs)
widely used in previous models23,47 that may not closely reca-
pitulate the unique properties of the brain endothelium48.
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Fig. 3 3D culture of astrocytes with AQP4 polarization in the BBB chip. a, b Representative morphology of human astrocyte (HA) cultured on a Matrigel-
coated 2D surface (a) and in 3D Matrigel (b) (GFAP, white; DAPI, blue) (scale bars= 50 µm). c Cell body size of HAs cultured in 2D and 3D (n= 69 for
2D and 39 for 3D, ***p < 0.005 by student t-test). d Process length of HAs cultured in 2D and 3D (n= 1352 for 2D and 1302 for 3D, ****p < 0.001 by
student t-test). e Gene expression of reactive gliosis markers in HAs cultured in 2D and 3D (n= 4 for each condition, ***p < 0.005 and ****p < 0.001 by
student t-test). f, g Gene expression of lipocalin-2 (LCN2) in HAs cultured on a Matrigel-coated 2D surface (f) and within 3D Matrigel (g) with interleukin-
1β (IL-1β) treatment demonstrating the ability to model reactive astrocytes more effectively in 3D (n= 4 for each condition, **p < 0.01, ***p < 0.005, and
****p < 0.001 by student t-test). h Quantitative analysis of AQP4 polarization by measuring AQP4 distribution in vascular and parenchymal side in the
perivascular channel. i Co-localization of AQP4 (AQP4, yellow) and α-syn (α-syn, magenta) at astrocytic end-feet (scale bars= 20 µm). j Distribution of
AQP4 (AQP4, yellow) along the cell bodies of HAs (GFAP, white; DAPI, blue) in the channel (scale bars= 50 µm). k Polarized expression of AQP4 to the
vascular side in the perivascular channel (n= 4 for each condition, *p < 0.05 by student t-test). Data are presented as mean ± s.e.m. All images are
representative ones from at least five biological and three technical replicates.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13896-7
6 NATURE COMMUNICATIONS |          (2020) 11:175 | https://doi.org/10.1038/s41467-019-13896-7 | www.nature.com/naturecommunications
Immortalized human brain endothelial cells are good candidates
for standardized screenings due to their availability as well as
indefinite proliferation while preserving their properties. Previous
studies using hCMEC/D3 in microfluidic BBB models showed
their barrier function with junctional protein expression, TEER49,
and permeability47. In our present study, we have used HBMEC
as it has been reported that HBMEC is the most suitable and
promising immortalized human brain endothelial cell line among
the four available cell lines (hCMEC/D3, HBMEC, TY10, and
BB19) for in vitro modeling of human BBB in terms of the barrier
tightness and permeability50. Moreover, the use of HBMECs
validated their BBB-specific function with their increased gene
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expressions of BBB-specific proteins in the presence of pericytes
and astrocytes.
We have demonstrated the tight barrier integrity of our BBB
model with the permeability coefficients comparable to those
measured in vivo37. In addition to our evaluation of the barrier
function with molecular permeability (permeability coefficient
analysis), we measured the TEER values from the electrode wires
inserted in the end of the inlet and outlet of the channels, as
shown in previous studies51–53, in order to cross-validate the
barrier function difference between our models in the same device
(not comparing them with Transwell or other models). We note
that 3D astrocyte-laden hydrogel in the lower channel prevents
electrodes from being coated along the bottom hydrogel channel
as reported in recent studies22,54. We also note that the TEER
values measured in our current study can be affected by the
uneven distribution of the potential across the membrane and
may not indicate the accurate values of the cell layer resistance as
reported in recent studies55–57. The TEER values measured in this
study thus were simply used to compare the barrier integrity
between the EC only and the BBB models in the same device for
the purpose of cross-validation of permeability coefficient ana-
lysis. For more information, we have included the raw resistance
data in Supplementary Table 2.
Our BBB chip incorporated 3D culture of HAs into the cellular
organization in order to recapitulate the BBB physiology and
integrity. We demonstrated reduced astrogliosis in 3D-cultured
HAs of an in vitro BBB model with the decreased expression of
reactive gliosis markers as well as the in vivo-like morphology. A
recent significant study has shown that LCN2 is a reactive
astrocyte-specific marker that is commonly induced in patholo-
gical conditions, whereas intermediate filament proteins such
as GFAP and VIM are normally expressed by astrocytes in both
physiological and pathological conditions29. We demonstrated
that LCN2 expression in HAs cultured in 3D was lower than in
those cultured on 2D and more importantly that IL-1β treatment
was more effective in 3D than in 2D, indicating the greater value
for neuroinflammation modeling. Our results suggest that the
cells restore their normal responses in 3D, while they are already
reactive in 2D culture without external stimulation, revealing that
studies that have used astrocytes in 2D culture may have over-
looked the potential reactivity in their model. Moreover, the
present BBB model shows the polarized distribution of AQP4 in
perivascular astrocytes, which is critical to mimic the BBB phy-
siology that maintains water and ion homeostasis in the brain.
AQP4 is also involved in brain pathophysiology including glial
scar formation58 and neuroinflammation59. Taken together, our
model established the physiologically relevant human BBB with
the ability to control status of astrocytes from resting to reactive
conditions as a potential for modeling of neuroinflammation and
reactive gliosis in CNS diseases.
The brain-blood ratio of a drug concentration, a key parameter
to estimate brain pharmacokinetics and brain-targeting efficiency,
has been previously assessed using rodents by in situ brain per-
fusion, brain microdialysis, and neuropharmacokinetic study60,61.
Given the complexity of the techniques and species differences
between humans and rodents, there is a critical need for the
strategies that quickly and reliably measure how much drugs can
penetrate to the brain parenchyma in a dose-dependent manner
at multiple time points62. Our BBB model integrated with precise
time-lapse sampling and end-point FACS analysis allowed us to
precisely quantify 3D nanoparticle distribution at the BBB.
Compartmentalized structure of the BBB chip conferred the
ability to measure the amount of molecules separately for each
space, allowing for quantitative assessment of BBB penetrations.
Quantitative analysis of cellular uptakes in the BBB chip enabled
us to evaluate the targeting efficacy of nanoparticles at cellular
levels. Moreover, our model provided an in depth mechanistic
understanding of the interactions between the BBB and nano-
particles at cellular levels.
To assess NP transport across the BBB, we used a HDL-
mimetic NP synthesized with our microfluidic technology, which
we recently reported63. Using our BBB chip, we demonstrated
that eHNP-A1 is a potential CNS drug delivery system with their
biomimetic ability to cross the BBB via SR-B1 mediated trans-
cytosis. Our approach to 3D mapping of nanoparticle distribu-
tions in the vascular and perivascular spaces at the BBB will
impact drug delivery and organs-on-chips areas.
In summary, we have presented a microengineered human
BBB platform with physiologically relevant structure and func-
tion, offering its application in quantitative assessment of CNS
drug delivery systems. Our BBB model allowed for multiple
analyses including TEER measurement, nanoparticle sampling,
and FACS analysis while the multiple devices were regulated by
multi-syringe racks at the same time (Supplementary Fig. 4a).
Microfluidic parallelization technology that integrates multiple
devices while preserving advantages of the microscale organ-on-
a-chip engineering will further provide higher throughput sys-
tem64. We believe that our human BBB model could provide a
widely useful tool for translational medicine research in particular
for the modeling of neuroinflammation and reactive gliosis in
neurological disorders.
Methods
Design and fabrication of the microfluidic device. The microfluidic device was
designed to have the widths of the upper, lower center, and lower side channels of
400 µm, 300 µm, and 200 µm, respectively. The height of all channels is 100 µm.
The microfluidic device was fabricated with polydimethylsiloxane (PDMS; Sylgard
184; Dow Corning, Midland, MI, USA) using soft lithography65. To create the
PDMS slab for the upper layer, PDMS pre-polymer (10:1 elastomer base to curing
agent, wt/wt) was degassed and poured onto silicon wafers patterned with SU-8
(Microchem, Newton, MA, USA). The thin PDMS sheet for the lower layer of the
device was created by spin coating an SU-8 patterned silicon wafer with a PDMS
pre-polymer to a height of 250 µm. After curing the PDMS pre-polymer for 1 h at
80 °C, inlets and outlets of the channels were formed with a 1 mm diameter biopsy
punch. A polycarbonate membrane (8 µm pore; Sterlitech Corp, Kent, WA, USA)
treated with 5% 3-aminopropyl-trienthoxysilane (APTES) solution (Sigma-Aldrich,
Fig. 4 On-chip BBB transport analysis of HDL-mimetic nanoparticles. a Discoidal engineered HDL-mimetic nanoparticle with apolipoprotein A1 (eHNP-
A1) consisting of lipid, apolipoprotein A1 and fluorescent marker. b Transmission electron microscopy (TEM) image of the synthesized eHNP-A1 (scale
bar= 20 nm). c Size distribution of the synthesized eHNP-A1. d Composition of the eHNP-A1. e Biodistribution of the eHNP-A1. f Quantification of the
relative fluorescence intensity in each organ (Data represent mean ± s.e.m from n= 4 for each condition). g eHNP-A1 accumulated in the mouse brain
(scale bar= 50 µm). h Schematic description of eHNP-A1 distribution in the BBB model showing (1) eHNP-A1 remaining in the vascular channel, (2) eHNP-
A1 interact with endothelial cells (HBMECs), (3) eHNP-A1 translocated to the perivascular channel, and (3-1) eHNP-A1 interact with astrocytes (HAs).
i, j Confocal images showing eHNP-A1 within the HBMEC monolayer (i) and HAs (j) in a BBB chip (scale bars= 50 µm). k, l Relative fluorescence intensity
of sampled culture medium containing eHNP-A1 from the upper channel (k) and the lower channel (l) after 2 h of eHNP-A1 incubation in the vascular
channel (k: n= 12; l: n= 5, **p < 0.01 by student t-test). Data show mean ± s.e.m. m, n Distribution of eHNP-A1 in control (m) and the block lipid transport-
1 (BLT-1) treated microengineered BBB model (n). o, p Representative fluorescence-activated cell sorting (FACS) plot for the numbers of eHNP-A1 positive
HBMECs and HAs in control (o) and BLT-1 treated BBB models (p). q Cellular uptake of eHNP-A1 in the BBB chip quantified from FACS analysis (n= 3).
Data are presented as mean ± s.e.m. All images are representative ones from at least three biological and three technical replicates.
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St. Louis, MO, USA)66 was sandwiched and bonded between the upper and lower
PDMS layers using a plasma cleaner (Harrick Plasma, Ithaca, NY, USA). The
fabricated device was then placed in a polystyrene box (Ted Pella, Redding, CA,
USA). The device and microchannels are sterilized with 70% ethanol and placed in
a dry oven at 80 °C for 2.5 days to restore hydrophobicity of the PDMS surface.
Computational fluid dynamics. Serum transport in the microfluidic channels was
modeled with COMSOL (COMSOL, Multiphysics 5.3a, Stockholm, Sweden). The
convection-diffusion equation was solved using the chemical species transport
module. The diffusion coefficient of serum was assumed to be 5.9 × 10−11 m2 s−1 in
culture medium67, and 8.0 × 10−11 m2 s−1 in Matrigel68. The initial serum con-
centrations of culture medium and Matrigel was taken as 5 × 10−3 mol m−3 and 0
mol m−3, respectively. Matrigel and the porous membrane were defined as a
porous medium with porosity value of 0.8 and 0.016, respectively. The computa-
tional simulation was performed within a microfluidic device without cellular
components. The three-dimensional model was used with no-slip boundary con-
ditions on all the walls, and the numerical grid for performing the simulations
consisted of ~850,000 finite elements.
Cell culture. Immortalized human brain microvascular endothelial cells (HBMEC;
Innoprot, Bizkaia, Spain; #P10361-IM) at passage 5–10 were maintained in
endothelial cell medium (Sciencell, San Diego, CA, USA) on flasks coated with 50
μg mL−1 fibronectin (Sigma-Aldrich). Human brain vascular pericytes (HBVP;
Sciencell; #1200) and human astrocytes (HA; Sciencell; #1800) were cultured on 1
mgmL−1 poly-L-lysine (PLL, Sigma-Aldrich) coated flasks and maintained in
astrocyte and pericyte medium, respectively (Sciencell). Both primary cells between
passages 3 and 5 were used for all experiments. Fibronectin and PLL coating
procedures were achieved following the manufacturer’s instruction. To optimize
cell culture condition, cell metabolic activity in different medium condition were
quantified using a (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) (MTS) assay (n= 6), which measures the for-
mazan product by cell metabolic activity. CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega, Madison, WI, USA) was added to HBMECs,
HBVPs, and HAs cultured in Endothelial cell medium (E), Astrocyte medium (A),
Pericyte medium (P), Microglia medium (M; Sciencell), E+G (E:A:M= 1:1:1:1),
and E+ P+G (E:P:A:M= 1:1:1:1) after 3 days of culture. Here, we describe 1:1
mixture of A and M as glial cell medium (G). After 4 h of incubation, the optical
absorbance of each sample was measured at 490 nm using Cytation 5 plate reader
(BioTek, Winooski, VT, USA). To compare HAs in 2D and 3D, HAs were seeded
at a density of 1 × 106 cells mL−1 in Matrigel (Growth factor-reduced; Corning,
NY, USA) coated 24 wells and in 3D Matrigel (5 mgmL−1). After 1 day of culture,
cells were stimulated with 1 ng mL−1 and 10 ng mL−1 of recombinant human
interleukin-1-beta (IL-1β; Gibco, Grand Island, NY, USA) and incubated for
another 20 h for analysis.
Construction of the BBB chip system. Prior to seeding HBVPs into the center
channel of the lower layer, the channel was coated with 50 µg mL−1 fibronectin
(Sigma-Aldrich) for 1 h at 37 °C while the device was placed upside down. Then
HBVPs were seeded at 1 × 107 cells mL−1 density into the center channel and
incubate for 6 h to allow adhesion of cells onto the fibronectin-coated poly-
carbonate membrane. Then 1 × 106 HAs suspended in a 100 μL of Matrigel solu-
tion (Growth factor-reduced; Corning) were seeded into the same channel that
HBVPs are cultured. The final concentration of Matrigel was calculated to be 5 mg
mL−1. After gelation of Matrigel in the channel by incubating at 37 °C for 30 min,
cell culture medium was filled into the two side channels to avoid the gel drying
out. The device was placed in the incubator at 37 °C for 6 h, and the upper luminal
channel of the device was coated with 50 µg mL−1 fibronectin for 1 h at 37 °C.
HBMECs were then seeded into the upper channel with the density of 7 × 107 cells
mL−1. The final cell number ratio between HBMECs and HBVPs in a device was
1.5:1, and the ratio between HBMECs and HAs was 2:1, which was optimized for
HAs to cover ~99% of the perivascular surface of the endothelium. After 24 h of
culture to stabilize cells in the microfluidic device, the upper channel was con-
nected to PhD Ultra syringe pumps (Harvard Apparatus, Holliston, MA, USA) and
exposed to the media flow with the flow rate of 16 µLmin−1 to give cells the shear
stress of 4 dyne cm−2, which corresponds to the shear stress levels in the brain36.
Real-time qRT-PCR. Cell-specific gene expressions were quantified by qRT-PCR
analysis. Briefly, total RNA from HBMECs and HAs were isolated and collected
using the RNeasy Mini kit (Qiagen GmBH, Hilden, Germany). The amount of
collected RNA samples were measured by Cytation 5 plate reader and 800 ng
(HBMEC) and 280 ng (HA) of RNA were reverse-transcribed into cDNA with T100
Thermal Cycler (Bio-Rad, Hercules, CA, USA) using High-capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA, USA). To analyze endo-
thelial specific gene expressions in HBMECs (n= 3), microfluidic qRT-PCR was
performed with Flex Six IFC (Fluidigm, South San Francisco, CA, USA) using the
Fluidigm Biomark system (Fluidigm). To analyze glial reactivity of HA in 2D and 3D
culture system (n= 4), standard qRT-PCR was performed with a StepOnePlus Real-
Time PCR system (Applied Biosystems) using TaqMan Fast Universal PCR Master
Mix (Applied Biosystems). The target genes were assessed using commercially
available primers (GFAP: Hs00909233_m1, VIM: Hs00958111_m1, LCN2:
Hs01008571_m1, VWF: Hs01109446_m1, SELE: Hs00174057_m1, PECAM1:
Hs01065279_m1, VECAD (CDH5): Hs00901465_m1, OCLN: Hs00170162_m1,
ZO-1 (TJP1): Hs01551861_m1, CAT1 (SLC7A1): Hs00931450_m1, LAT1
(SLC7A5): Hs00185826_m1, OCT1 (SLC22A1): Hs00427552_m1, GLUT1
(SLC2A1): Hs00892681_m1, CERP (ABCA1): Hs01059137_m1, P-GP (ABCB1):
Hs00184500_m1, MRP1 (ABCC1): Hs01561483_m1, LRP1: Hs00233856_m1,
AGER: Hs00542584_g1, ICAM1: Hs00164932_m1, VCAM1: Hs01003372_m1;
Applied Biosystems; All primers are also listed in Supplementary Table 1). The
results were quantified by the comparative Ct method. Ct values for samples were
normalized to the expression of the housekeeping gene, glyceraldehyde 3-phosphate
dehydrogenase (GAPDH: Hs02786624_g1; Applied Biosystems).
Immunocytochemistry. To visualize cell-specific marker expression, immunocy-
tochemistry was performed. Briefly, samples were fixed with 2% paraformaldehyde
(PFA; Santa Cruz Biotechnology, San Diego, CA, USA) for 15 min at RT. After
permeabilizing in 0.1% Triton X (Sigma-Aldrich) in PBS for 15 min, the samples
were blocked with 2% bovine serum albumin (BSA; Sigma-Aldrich) in PBS for 1 h
at RT. Subsequently, the samples were incubated with primary antibodies at 4 °C
overnight, washed three times with 1% BSA. The following antibodies were used
for immunocytochemistry: goat anti-ZO-1 (1:200; Abcam, Cambirdge, MA, USA),
mouse anti-GFAP (1:200; Invitrogen, Carlsbad, CA, USA), rabbit anti-S100β
(1:200; Invitrogen), rabbit anti-Phospho eNOS (Ser1177) (1:200; Invitrogen),
AlexaFluor 488 conjugated rabbit anti-α-SMA (1:200; Abcam), and rabbit anti-
AQP4 (1:200; Invitrogen). Then samples were incubated with fluorescence-
conjugated secondary antibodies (donkey anti-goat AlexaFluor 633 (1:200; Invi-
trogen), chicken anti-mouse AlexaFluor 594 (1:200; Invitrogen), and donkey anti-
rabbit AlexaFluor 647 (1:200; Abcam)) for 6 h at 4 °C to visualize the targets. Nuclei
were counterstained with 4,6-diamino-2-phenylindole (DAPI; Invitrogen) and
stored in PBS before imaging. Fluorescently visualized samples were examined
using a confocal microscope (LSM 700, Carl Zeiss, Oberkochen, Germany).
Permeability measurement. After 60 h of culture, culture medium containing
500 µg mL−1 of 4 kDa or 40 kDa FITC-dextran (Sigma-Aldrich) was introduced
into the luminal channel of the device at 16 µL min−1 with a PhD Ultra syringe
pump (Harvard Apparatus). Simultaneously, culture medium from one side
channel was sampled at 4 µL min−1 with a syringe pump for 1 h. Fluorescence
intensities of 500 µg mL−1 of FITC-dextran solution and the sampled solutions are
measured using a Cytation 5 plate reader (n= 4 for each condition). The dextran
concentrations in the solutions were calculated with the measured fluorescence
intensity values using a standard calibration curve. Permeability coefficients were
calculated using the following equation:
P ¼ V
dC
dt
ΔC
ð1Þ
Where V is the volume of the sampled solution, A is the surface area of the
endothelial barrier, dCdt is the concentration change in the abluminal space along
time, and ΔC is the concentration difference across the barrier.
TEER measurement. The TEER of the endothelial monolayer formed in the device
was measured using a custom electrode adapter30,65 made with Rj11 plug and Ag,
Ag/AgCl electrode wires (381 μm in diameter and 3 cm in length, A-M Systems,
Sequim, WA, USA) connected to EVOM2 volt-ohmmeter (Word Precision
Instruments, Sarasota, FL, USA) which generates a constant 10 µA of AC current at
12.5 Hz while measuring resistance. To reduce background resistance and error, the
electrode wires were placed in a tygon tubing (1/32“ID x 3/32“OD, Cole-Parmer,
Vernon Hills, IL, USA) filled with culture medium and inserted into the channels
(Supplementary Fig. 11). After 1 min of stabilization, 5 multiple readings were
averaged for each device. To calculate TEER, the measurements from the chips in
the absence of the cells were subtracted from the resistance of each device, and then
the values were multiplied by the surface area of endothelial monolayer overlapping
with the lower channel (0.015 cm2).
Image analysis. Quantitative analysis of cell distribution, cell morphology, and
AQP4 polarization were performed using ImageJ (NIH, Bethesda, MD, USA). For
cell distribution analysis, fluorescence intensity profile of each color (red, green,
and white) was analyzed using Matlab (Mathworks, Natick, MA, USA). To analyze
the morphology of HAs, the boundaries of cells were obtained automatically using
magic wand tool on the maximal intensity projection image. Distribution of AQP4
was quantified by measuring the fluorescence intensity profile along the z-axis in z-
stack images of the perivascular channel using ImageJ. The lower channel was
divided into the two spaces (top half—vascular side, bottom half—parenchymal
side) and the average of the fluorescence intensity from each space was calculated.
The averaged intensity within the top half space (vascular side) was divided by the
averaged intensity within the bottom half space (parenchymal side) to calculate the
AQP4 polarization index.
Nanoparticle synthesis. The microvortex propagation mixer (µVPM) that we
reported previously63 was used for the synthesis. Briefly, the µVPM was connected
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13896-7 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:175 | https://doi.org/10.1038/s41467-019-13896-7 |www.nature.com/naturecommunications 9
to syringe pumps (Harvard Apparatus) to introduce the solutions into the device.
The precursor solutions including a lipid solution that was composed of 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC; Avanti Polar Lipids, Alabaster,
AL, USA) with a concentration of 2.75 mgmL−1 in ethanol, and a apolipoprotein
A1 from human plasma (Sigma-Aldrich) with a concentration of 0.2 mg mL−1 in
PBS were added into the mixer. The flow ratio between the side streams and the
center stream in the mixer was 5.5:1. The mixed solution was collected and then
washed three times with PBS using a 10,000M.W. centrifugal filter (EMD Milli-
pore, Darmstadt, Germany) at a speed of 2585 × g for 20 min. The size distribution
of the final sample was measured with a Zetasizer Nano ZS (Malvern Instruments,
Worcestershire, United Kingdom). Fluorescently labeled eHNPs were synthesized
with 1,1′-Dioctadecyl-3,3,3′,3′-Tetramethylindotricarbocyanine Iodide (DiR′;
Invitrogen) or a modified lipid precursor solution containing 15% (w/w) 1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfo-
nyl) (Rhodamine-DMPE; Sigma-Aldrich). The amount of protein of the final
sample was quantified using the Micro BCA Protein Assay kit (Invitrogen).
Biodistribution study. All animal experiments were reviewed and approved by the
Georgia Tech’s Institutional Animal Care and Use Committee. 4–5 week-old male
balb/c mice (Jackson Labs, city, state, USA) were given an irradiated dietary
regiment until the mice were 21–22 weeks of age. For biodistribution study, 1 mg
kg−1 of eHNP-A1 was systemically administered to the mouse via tail vein
injection. Injection of 200 μL saline was served as control. 24 h after administration,
mice were sacrificed and perfused with saline and 4% PFA for 15 min. Then organs
(brain, heart, lung, liver, kidneys, and spleen) were harvested to visualize their DiR
content using an in vivo imaging system (IVIS; Perkin Elmer, Waltham, MA,
USA). To visualize the eHNP-A1 internalization inside the brain tissue, the har-
vested brain tissues were cryosectioned into 10 µm slices and stained with DAPI
using the DAPI-containing antifade mounting medium (H-1200; Vector Labora-
tories, Burlingame, CA, USA). The slides were then imaged under a confocal
microscope (Zeiss LSM 780).
Nanoparticle distribution study in a chip. Culture medium containing eHNP-A1
at a concentration of 10 µg mL−1 was introduced into the upper channel of the
device. To block the NP transport via SR-B1, 200 µM of BLT-1 (Sigma-Aldrich)
was treated in the upper channel for 1 h prior to the NP incubation. Following 2 h
of NP incubation with culture medium with or without BLT-1 (200 µM), 10 µL of
culture medium was sampled from the upper channel. The upper channel was
washed with PBS and filled with Dispase (Corning) to digest Matrigel in the lower
channel. After 30 min, 10 µL of the mixture of the culture medium and digested
Matrigel from the lower channels were collected. To measure the concentrations of
nanoparticles, fluorescence intensities of the culture medium injected into the
upper channel, sampled from the upper channel (n= 14 for control and n= 13 for
BLT-1), and the culture medium sampled from the lower channels (n= 7 for
control and n= 5 for BLT-1) were measured using the Cytation 5 plate reader.
Nanoparticle uptake study using flow cytometric analysis. Prior to seeding cells
into the device, HBMECs and HAs were fluorescently labeled with CellTracker
(Deep Red and Green CMFDA, respectively; Invitrogen) as per manufacturer’s
instructions. After 2 h of 10 µg mL−1 of NP incubation in the upper channel of the
device, the devices were washed three times with PBS and 0.25% Trypsin-EDTA
(Invitrogen) and Dispase (Corning) were injected into the upper channel and lower
side channels, respectively. HBMECs and HAs were then collected in culture
medium and spun down at 200 × g for 5 min. Then cell mixture was fixed in 4%
PFA (Santa Cruz Biotechnology) for 30 min and stored in ice-cold FACS buffer
(PBS with 2% FBS (Invitrogen)) at 4 °C. The HBMEC and HA fractions in total
sample (n= 5 for control and n= 6 for BLT-1) were obtained by BD FACSAria III
Cell Sorter (BD Biosciences, San Jose, CA, USA) and quantitatively analyzed using
FlowJo software (FlowJo LLC, Ashland, OR, USA). Debris and doublets were
excluded using FSC-A/SSC-A, FSC-A/FSC-W, respectively. The cells were then
gated for the appropriate markers for the cell type (Supplementary Fig. 12).
Calculation of nanoparticle distribution on a chip. Loss of the injected NPs in a
device due to their non-specific adsorption to the PDMS surface was measured by
sampling the NP solution after 2 h of incubation in a device consisting of a single-
layer of the vascular channel. The NP distribution in HBMECs was calculated as
follows:
HBMECuptakecalculationð Þ ¼ ðTotal injected 100%ð ÞSamplingÞ  ðLosssamplingÞ
 ðVascularSamplingÞ  ðPerivascularSamplingÞ
ð2Þ
Where (VascularSampling), (PerivascularSampling), and (Total injeceted)(100%)Sampling)
are fluorescence intensities of NP solutions sampled from the vascular channel,
perivascular channel, and injected solution, (Losssampling) is the loss of NPs in a device
measured by sampling, and (HBMEC uptakecalulation) is percentages calculated by the
equation.
Statistics analyses. Data are presented as mean ± standard error of the mean
(s.e.m.) unless otherwise stated. All statistical analyses were done using GraphPad
Prism 6 (GraphPad Software, La Jolla, CA). Unpaired Student’s t-tests was applied
and p-values of < 0.05, 0.01, 0.005, and 0.001 were considered significant in all tests.
All chip experiments were reproduced for at least two times to confirm data
reliability. Per experiment, at least two biological and technical replicates were used.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in this published article
(and its supplementary information files), or are available from the corresponding author
on reasonable request.
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